A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

NCT00551213 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: Robatumumab
DRUG: Irinotecan
BIOLOGICAL: Cetuximab
DRUG: Capecitabine
DRUG: FOLFOX
DRUG: CAPEOX/XELOX
DRUG: FOLFIRI

Sponsor

Merck Sharp & Dohme LLC